GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Forward PE Ratio

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Forward PE Ratio : 0.00 (As of Apr. 25, 2024)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Forward PE Ratio?

abrdn Life Sciences Investors's Forward PE Ratio for today is 0.00.

abrdn Life Sciences Investors's PE Ratio without NRI for today is 16.43.

abrdn Life Sciences Investors's PE Ratio for today is 16.43.


abrdn Life Sciences Investors Forward PE Ratio Historical Data

The historical data trend for abrdn Life Sciences Investors's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Forward PE Ratio Chart

abrdn Life Sciences Investors Annual Data
Trend
Forward PE Ratio

abrdn Life Sciences Investors Semi-Annual Data
Forward PE Ratio

Competitive Comparison of abrdn Life Sciences Investors's Forward PE Ratio

For the Asset Management subindustry, abrdn Life Sciences Investors's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's Forward PE Ratio Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Forward PE Ratio falls into.



abrdn Life Sciences Investors Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


abrdn Life Sciences Investors  (NYSE:HQL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


abrdn Life Sciences Investors Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2022

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 05-18-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-16-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-12-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 05-17-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022